Quantcast

Latest Gemfibrozil Stories

2011-08-11 12:45:17

Type 2 diabetes patients, who face higher risk of cardiovascular disease, often take a combination of medications designed to lower their LDL or "bad" cholesterol and triglyceride levels while raising their HDL or "good" cholesterol because doctors long have thought that taken together, the drugs offer protection from heart attacks and improve survival.

2011-06-28 13:22:58

Cardiovascular disease (CVD), driven by the global pandemics of obesity and diabetes, poses a daunting challenge to clinicians in the 21st century.

2011-03-22 23:31:26

Although recent evidence suggests that the clinical benefit may be uncertain for fibrates, a class of drugs used for the treatment of high lipid levels, use of these drugs is common in the U.S. and Canada, with usage increasing steadily in the last decade in the U.S., especially for a brand-name fibrate product.

2010-07-26 13:04:28

The European Society of Cardiology (ESC) is concerned that interpretations of a paper about cholesterol, published in the Lancet (1), could act to deter ongoing research efforts into developing new therapeutic strategies to increase high density lipoprotein (HDL) cholesterol.

2009-12-15 16:58:00

WILMINGTON, Del., Dec. 15 /PRNewswire-FirstCall/ -- The U.S.

2009-06-04 06:45:00

ABBOTT PARK, Ill. and LONDON, June 4 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) and AstraZeneca announced today that the companies have submitted a New Drug Application (NDA) to the U.S.

2009-03-29 11:50:00

ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- A new analysis from the JUPITER study shows that CRESTOR(R) (rosuvastatin calcium) 20mg significantly cut the risk of venous thromboembolism (VTE) by 43% (p =0.007) compared to placebo among men and women with low to normal cholesterol levels and elevated high-sensitivity C-reactive protein (hsCRP).

2009-03-29 11:46:00

ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Results from a new sub- analysis of the JUPITER study show that patients with low to normal cholesterol levels and elevated high sensitivity C-reactive protein (hsCRP) who attained a dual treatment target of LDL-C <70mg/dL and hsCRP <2mg/L with CRESTOR(R) (rosuvastatin calcium) 20mg achieved a greater reduction in cardiovascular events compared to placebo than those who did not (65% vs 36%; p=0.033).

2009-03-29 11:38:00

ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- A new analysis from the JUPITER study shows that CRESTOR(R) (rosuvastatin calcium) 20mg significantly cut the risk of venous thromboembolism (VTE) by 43% (p =0.007) compared to placebo among men and women with low to normal cholesterol levels and elevated high-sensitivity C-reactive protein (hsCRP).


Word of the Day
aphotic
  • Having no light.
  • Of or relating to the region of a body of water that is not reached by sunlight and in which photosynthesis is unable to occur.
The word 'aphotic' comes from Greek roots meaning 'without' and 'light'.
Related